Moving PARP Inhibition Upfront: Why the Phase 3 TALAPRO-3 Trial Rewrites Treatment for HRR-Deficient mCSPC

A 24-Year Mortality Analysis of Spinal Muscular Atrophy and a Blueprint for Future Pediatric Care

A 24-year U.S. analysis shows gene-targeted therapies dramatically reduced childhood spinal muscular atrophy mortality, transforming a once-fatal disease into a manageable long-term condition.

Moving PARP Inhibition Upfront: Why the Phase 3 TALAPRO-3 Trial Rewrites Treatment for HRR-Deficient mCSPC

ASCO 2026 data suggest first-line talazoparib plus enzalutamide significantly delays progression in HRR-mutated metastatic prostate cancer, highlighting the growing importance of early genomic testing and biomarker-driven treatment.

A Clinical Translation and Deep-Dive Analysis of the Strong Heart Study

A landmark study found the APOE ε4 gene was not linked to vascular brain injury progression in American Indians, highlighting the importance of cardiometabolic risk management.

RADIOS Consortium Explores Immune Effects of Cancer Checkpoint Therapy

The RADIOS consortium studies immune-related side effects of cancer immunotherapy, helping researchers improve treatment safety, personalize care, and optimize outcomes for patients receiving checkpoint inhibitors.

Physical Work Demands May Increase Autoimmune Rheumatic Risk

Physically demanding occupations may increase autoimmune disease risk in men, particularly inflammatory joint conditions, highlighting the importance of workplace prevention, early screening, and risk assessment.